Tarsus Pharmaceuticals (TARS) revenue breakdown
By product, Product sales, net is the largest at 98% of fiscal 2024 revenue, growing 1122% a year over 1 years.
Revenue by product
Fiscal years, as Tarsus Pharmaceuticals reports them in its 10-K filings; fiscal 2024 total $183M.
| Products | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|
| Product sales, net | — | — | $15M | $180M | 98% |
| License fees and collaboration revenue | — | — | $3M | $3M | 2% |
| License fees | $53M | $24M | — | — | — |
| Collaboration revenue | $4M | $2M | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TARS.
Open TARS in InvestinglyQuestions
Where does Tarsus Pharmaceuticals make its money?
In fiscal 2024, by product: Product sales, net $180M, License fees and collaboration revenue $3M.
From Tarsus Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.